Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor

• Published in: Transfusion (Philadelphia, Pa.) Vol. 38; no. 7; pp. 663 - 668
• Main Authors: Stroncek, D.F., Jaszcz, W., Herr, G.P., Clay, M.E., McCullough, J.
• Format: Journal Article
• Language: English
• Published: Edinburgh, UK Blackwell Science Ltd 01.07.1998
• Subjects: Adult; Antigens, CD - immunology; Female; Flow Cytometry; GPI-Linked Proteins; Granulocyte Colony-Stimulating Factor - administration & dosage; Hematopoietic Stem Cell Mobilization; Humans; Isoantigens - immunology; Membrane Glycoproteins - immunology; Neutrophil Activation - drug effects; Neutrophils - drug effects; Neutrophils - immunology; Receptors, Cell Surface; Receptors, Fc - immunology
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1046/j.1537-2995.1998.38798346635.x

BACKGROUND:Granulocyte‐colony‐stimulating factor (G‐CSF) is becoming the standard agent for mobilizing granulocytes. Most granulocyte donors are given a single dose of G‐CSF, but in some cases they are given G‐ CSF for several days, and multiple granulocyte concentrates are collected. The administration of a single dose of G‐CSF induces several changes in the expression of neutrophil antigens, but the effects of multiple daily doses of G‐CSF are not known. STUDY DESIGN AND METHODS:Seven healthy people received 5 microg per kg of G‐CSF for 10 days. Their expression of several neutrophil antigens before, during, and after the administration of G‐CSF was analyzed through the use of flow cytometry. RESULTS:The expression of L‐selectin (CD62L), Fcgamma receptor (FcgammaR) III (FcgammaRIII, CD16), and the leukocyte function antigen (CD11a) decreased throughout the course of G‐CSF administration, while the expression of FgammaR I (FcgammaRI, CD64) and lipopolysaccharide‐binding protein receptor (CD14) increased. The expression of FcgammaR II (FcgammaRII, CD32) also increased, but not until the fourth day of G‐CSF administration. The expression of amino peptidase N (CD13), C3bi receptor (CD11b), and the neutrophil beta2 integrin unit (CD18) did not change during the administration of G‐CSF, but that of both CD13 and CD18 increased 3 days after the last dose. The expression of neutrophil‐specific antigen NB1 initially increased, returned to pre‐G‐CSF levels after 4 days, and then increased again after 10 days of G‐CSF administration. CONCLUSION: Changes in the expression of several neutrophil antigens occurred throughout a 10‐day course of G‐CSF Most of the changes occurred after one dose, but additional changes occurred later in the 10‐day course and after its completion. These changes may affect the function of G‐CSF‐mobilized granulocytes.